Insertion sites in fowlpox vectors

1. A recombinant fowlpox virus containing and capable of expressing at least one foreign gene inserted at an insertion site within the fowlpox virus genome,

wherein the insertion site is located (i) at a position corresponding to position 128178 of the fowlpox genomic sequence, (ii) at a position corresponding to a region between positions 67080 and 67097 in the fowlpox genomic sequence, (iii) at a position corresponding to a region between positions 7470 and 7475 in the fowlpox genomic sequence, or (iv) at a position corresponding to a region between positions 281065 and 281070 in the fowlpox genomic sequence wherein the fowlpox virus genome corresponds to SEQ ID NO:3.

2. The recombinant fowlpox virus of claim 1 , wherein the foreign gene encodes a marker, a therapeutic agent, or an antigenic determinant.

3. The recombinant fowlpox virus of claim 2 , wherein the foreign gene codes for an antigenic determinant selected from the group consisting of a pathogenic virus, a bacteria, other microorganism, a parasite, and a tumor cell.

4. The recombinant fowlpox virus of claim 2 , wherein the foreign gene codes for an antigenic determinant expressed in a pathogen, wherein the pathogen is selected from the group consisting of Plasmodium, Mycobacteriua , Herpes virus, influenza virus, hepatitis, and HIV.

5. The recombinant fowlpox virus of claim 1 , wherein the foreign gene is selected from the group of genes encoding hormones, growth factors, immunostimulatory molecules, enzymes, cytokines, receptors, and tumor suppressor genes.

6. A pharmaceutical composition, comprising the recombinant fowlpox virus of claim 1 .

7. A method for inducing an immunological response against at least one antigen in a mammal, said method comprising inoculating the mammal with at least a first recombinant fowlpox virus containing and capable of expressing at least the gene encoding said antigen inserted at an insertion site within the fowlpox virus genome,

wherein the insertion site is located (i) at a position corresponding to position 128178 of the fowlpox genomic sequence, (ii) at a position corresponding to a region between positions 67080 and 67097 in the fowlpox genomic sequence, (iii) at a position corresponding to a region between positions 7470 and 7475 in the fowlpox genomic sequence, or (iv) at a position corresponding to a region between positions 281065 and 281070 in the fowlpox genomic sequence wherein the fowlpox virus genome corresponds to SEQ ID NO:3.

8. The method of claim 7 , wherein said recombinant fowlpox virus further contains a gene encoding at least one immunostimulatory molecule.

9. The method of claim 7 , wherein said method further comprises inoculating the mammal with a second vector containing and capable of expression at least one additional gene.

10. The method of claim 9 , wherein said second vector contains a gene encoding at least one immunostimulatory molecule.

11. The method of claim 9 , wherein the second vector comprises an adenovirus vector.

12. The method of claim 9 , wherein the second vector comprises a recombinant vaccinia virus vector.

13. The method of claim 9 , wherein the second recombinant vector comprises a recombinant fowlpox virus vector.